ライフサイエンスコーパス: seminal plasma

1 s for the quantitation of HIV RNA in CSF and seminal plasma.

2 as by a partially purified protease(s) from seminal plasma.

3 ivation status did not change in response to seminal plasma.

4 is acquired as the result of exposure to the seminal plasma.

5 ction persisted when HSV-2 was introduced in seminal plasma.

6 had at least 1 herpesvirus detected in their seminal plasma.

7 ed by real-time polymerase chain reaction in seminal plasma.

8 entage can be significantly suppressed under seminal plasma.

9 ng principal aspects of the Ect1 response to seminal plasma.

10 in part, enhancement of bacterial growth by seminal plasma.

11 s simplex virus type 2 (HSV-2) introduced in seminal plasma.

12 plasma lipid levels, and HIV-1 RNA levels in seminal plasma.

13 albumin, another protein purified from human seminal plasma.

14 emoved inhibitory factors sometimes found in seminal plasma.

15 ar to the inhibition previously described in seminal plasma.

16 immunodeficiency virus type 1 (HIV-1) RNA in seminal plasma.

17 in blood plasma (4.24 log(10) copies/mL) or seminal plasma (3.55 log(10) copies/mL; P<.05, each comp

18 Median seminal plasma and blood plasma HIV-1 RNA concentrations

19 in these assays are typically purified from seminal plasma and contain many molecular forms (intact

20 quenced such a nuclease isolated from bovine seminal plasma and identified human, rat and mouse homol

21 Elevated levels of cytokines in the seminal plasma and prostatic secretions have been detect

22 nd lamivudine achieve high concentrations in seminal plasma and significantly reduce HIV-1 RNA.

23 e to the immunosuppressive activity of human seminal plasma and to the low immunogenicity of sperm.

24 od plasma were compared to those detected in seminal plasma and/or cerebral spinal fluid of six indiv

25 a1, TGF-beta2, and TGF-beta3 are abundant in seminal plasma, and Affymetrix microarray revealed that

26 ebrospinal fluid (CSF), saliva, breast milk, seminal plasma, and cervical-vaginal lavage fluid (CVL).

27 ociated with higher HIV-1 loads in blood and seminal plasma; and (5) CMV seminal reactivation increas

28 that they retain activity in the presence of seminal plasma are indicated.

29 synthases and secreted by the prostate into seminal plasma are thought to support reproduction, but

30 BPSA purified from prostate tissue and seminal plasma, as well as BPSA generated in vitro by mi

31 ecimens can be used as external controls for seminal plasma assays.

32 However, 8 men (27%) had measurable HIV-1 in seminal plasma at their last study visit, 4 with increas

33 Most men (77%) had HIV-1 RNA levels in seminal plasma below the limit of quantification during

34 A fraction isolated from llama seminal plasma by column chromatography was identified a

35 Quantitation of HIV-1 RNA in seminal plasma can be reliably accomplished using two co

36 In multivariate analysis, the presence of seminal plasma CMV (P = 0.04), detectable 2-long termina

37 The seminal plasma compartment was more dynamic than the blo

38 h an eightfold increase in virus load in the seminal plasma compartment.

39 ee viral populations in the blood plasma and seminal plasma compartments of men infected with subtype

40 Seminal plasma competitively inhibited binding of the mi

41 Median lamivudine blood and seminal plasma concentrations were 391.3 (range, 175.3-7

42 (25th-75th percentiles) zidovudine blood and seminal plasma concentrations were 64.2 (range, 48.4-206

43 Western blot analysis of llama and bull seminal plasma confirmed immunorecognition of OIF using

44 the possibility that endometrial exposure to seminal plasma could contribute to endometriotic disease

45 Standardization of seminal plasma derived PSA calibrant molecular form mass

46 Several other cytokines present in seminal plasma did not elicit Ect1 cell responses.

47 nocytes in the presence of high dilutions of seminal plasma did not express CD1a but showed high leve

48 uspension matrices that used blood plasma or seminal plasma did not make a difference in recovery of

49 h urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seroposi

50 Pooled human seminal plasma enhanced E. coli growth in vitro in a dos

51 These data suggest that seminal plasma enhances the formation of endometriosis-l

52 lipid levels; and no detectable HIV-1 RNA in seminal plasma from all 8 participants tested.

53 Exposure to seminal plasma from HIV-1-infected and uninfected men wi

54 Seminal plasma from llamas and bulls was used as represe

55 This is a human seminal plasma glycoprotein that is immunologically indi

56 efore therapy, 4 men had HIV-1 RNA levels in seminal plasma >6.0 log10 (1 million) copies/mL, markedl

57 nce of an ovulation-inducing factor (OIF) in seminal plasma has broad implications and evokes questio

58 There was no significant change in seminal plasma HIV-1 RNA concentrations during the 2-wee

59 CD4 cell counts and blood plasma and seminal plasma human immunodeficiency virus type 1 (HIV-

60 ressed HIV-1 RNA levels to <400 copies/mL in seminal plasma in the majority of patients, the first di

61 ntagonists, and signaling inhibitors ablated seminal plasma induction of GM-CSF and IL-6, but did not

62 We found that seminal plasma interfered with the activity of PRO 2000

63 Given that seminal plasma is an abundant source of transforming gro

64 We conclude that OIF in seminal plasma is beta-NGF and that it is highly conserv

65 Seminal plasma is not just a carrier for spermatozoa.

66 By promoting a tolerogenic profile in DCs, seminal plasma might favor fertility, but might also com

67 ral blood mononuclear cells (PBMCs; n = 72), seminal plasma (n = 20), cerebrospinal fluid (CSF; n = 3

68 detectable (<400 copies/mL) in the blood and seminal plasma of 8/9 subjects after initiation of thera

69 beta, we evaluated the effect of exposure to seminal plasma on the growth of endometrial lesions.

70 prevented the tolerogenic effect induced by seminal plasma on the phenotype and function of DCs, sug

71 nsmitted viruses were evident in the donor's seminal plasma (one of five cases) and even more so in t

72 Human endometrial explants were exposed to seminal plasma or to control medium before transfer to P

73 HIV-1 RNA from blood plasma, seminal plasma, or cervical wicks was quantified at base

74 = 0.09) and more frequent shedding of CMV in seminal plasma (p = 0.002).

75 ce were protected if virus was introduced in seminal plasma (P=.0007, log rank test).

76 83% were blood plasma positive and 63% were seminal plasma positive.

77 However, other forms of inactive seminal plasma prostate-specific antigen, either intact

78 have a role in the physiologic processing of seminal plasma proteins such as pro-PSA, as well as in t

79 To this end, seminal plasma purified PSA standards from different com

80 measured in log(10) RNA copies/milliliter of seminal plasma) ranging from 0.11 to 0.32; those of the

81 In this study, we show that seminal plasma redirects the differentiation of human de

82 iologically relevant events, the addition of seminal plasma resulted in enhanced virion binding to ep

83 In addition, HIV-1 virions in seminal plasma samples harbored dramatically higher leve

84 with paired blood plasma and CVL, saliva, or seminal plasma samples revealed 91% were blood plasma po

85 When HIV-1 virions were incubated with seminal plasma samples, infectivity in initially nondivi

86 .05) elevation in high grade prostate cancer seminal plasma samples.

87 Xenografts exposed to seminal plasma showed an eightfold increase in volume an

88 HIV-1 RNA was measured in seminal plasma (SP) and blood plasma (BP) at baseline, o

89 Antiretroviral pharmacology in seminal plasma (SP) and rectal tissue (RT) may provide i

90 accelerated dramatically in the presence of seminal plasma (SP) and that agitation is not required f

91 Therefore, seminal plasma (SP) collected from healthy individuals w

92 triple therapy donated blood plasma (BP) and seminal plasma (SP) during therapy.

93 and SF162 after incubation with centrifuged seminal plasma (SP) from HIV-negative donors and assesse

94 c concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influenc

95 etroviral drug families on viral kinetics in seminal plasma (SP) of treatment-naive HIV-infected pati

96 f the intrinsic anti-HIV-1 activity of human seminal plasma (SP) was determined to reside in the cati

97 and of the transmembrane C regulator CD46 in seminal plasma (SP).

98 HIV-RNA was quantified in seminal plasma (spVL) and in blood plasma (bpVL) from 2

99 Seminal plasma stimulated the production of a variety of

100 = .002), despite a more sensitive assay for seminal plasma than for cervical wicks.

101 lls were used to investigate agents in human seminal plasma that induce a proinflammatory response.

102 all three TGF-beta isoforms as key agents in seminal plasma that signal induction of proinflammatory

103 he HIV-1 RNA viral loads was observed in the seminal plasma values than in the blood plasma values wh

104 All macaques were systemically infected, and seminal plasma virion-associated RNA (vRNA) levels were

105 Absence of seminal plasma was accompanied by down-regulation of the

106 Seminal plasma was assayed for HIV-1 RNA and semen was c

107 The concentration of HIV-1 RNA in seminal plasma was monitored as a potential surrogate ma

108 os developed in female tracts not exposed to seminal plasma were abnormal from the early cleavage sta

109 dine, lamivudine, and HIV-1 RNA in blood and seminal plasma were measured in 9 HIV-positive men over

110 Viral loads in whole semen and seminal plasma were strongly correlated with blood plasm

111 ml (range, <400 to 2.8 x 10(5) copies/ml) in seminal plasma, which is 10- to 1,000-fold higher than p